PANZO 40 Tablet

គុណភាពព្យាបាល
ឱសថនេះមានមុខងារបញ្ឈប់ការបញ្ចេញអាស៊ីតក្រពះ។ ប្រើក្នុងរយៈពេលខ្លី៖
- ដំបៅគល់ពោះវៀនតូច
- ដំបៅក្រពះ
- រលាកបំពង់អាហារ ដោយការច្រាល់ទឹកអាស៊ីតពីក្រពះ
- ដំបៅគល់ពោះវៀនតូច ដោយមេរោគ Helicobacter Pylori (ត្រូវព្យាបាលរួមជាមួយឱសថផ្សះអង់ទីប៊ីយ៉ូទិកផ្សេងទៀត)។
កម្រិតនិងរបៀបប្រើ
- ឱសថនេះត្រូវលេបទាំងមូលជាមួយទឹកបន្តិច 1ថ្ងៃ1ដង មុនពេលទទួលទានអាហារពេលព្រឹក។
- ព្យាបាលដំបៅគល់ពោះវៀនតូច (Duodenal ulcer): លេបម្ដង1គ្រាប់(40mg) 1ថ្ងៃ1ដង នៅពេលព្រឹករយៈពេល 2-4សប្ដាហ៍។ ប្រសិនបើការរលាកឬដំបៅគល់ពោះវៀននោះបង្កឡើងរួមជាមួយមេរោគ Helicobacter Pyloriនោះ ត្រូវព្យាបាលជាមួយឱសថអង់ទីប៊ីយ៉ូទិចបន្ថែមទៀត។
- ព្យាបាលដំបៅក្រពះ: លេបម្ដង1គ្រាប់(40mg) 1ថ្ងៃ1ដង នៅពេលព្រឹករយៈពេល 4-8សប្ដាហ៍។
- ព្យាបាលរលាកបំពង់អាហារ ដោយការច្រាល់ទឹកអាស៊ីតក្រពះ: លេបម្ដង1គ្រាប់(40mg) 1ថ្ងៃ1ដង នៅពេលព្រឹករយៈពេល 4-8សប្ដាហ៍។
ចំពោះមនុស្សចាស់ អ្នកខ្សោយតម្រងនោម និងអ្នកខ្សោយថ្លើម មិនចាំបាច់កែប្រែកម្រិតប្រើទេ។

For the short-term treatment of duodenal ulcer, gastric ulcer and reflux esophagitis. If the duodenal ulcer has been demonstrated to be associated with Helicobacter pylori infection.

Pantoprazole 40 used in combination with appropriate antibiotics may be useful.

Dosage and direction for use

The recommended once daily dosage should be taken in the morning. Pantoprazole 40 should be swallowed whole with a little water either before or during breakfast.

Duodenal ulcer

The recommended oral dosage is 40mg pantoprazole once daily in the morning for 2-4 weeks. If the duodenal ulcer has been demonstrated to be associated with Helicobacter pylori infection, Pantoprazole 40 used in combination with appropriate antibiotics may be useful.

Gastric ulcer

The recommended oral dosage is 40mg pantoprazole once daily in the morning for 4-8 weeks. In case of a suspected gastric ulcer, malignancy of the ulcer should be excluded, as treatment could conceal the symptoms and may delay diagnosis.

Reflux oesophagitis

The recommended oral dosage is 40mg pantoprazole once daily in the morning for 4-8 weeks.

Elderly patients

No dosage adjustment is necessary in the elderly.

Impaired renal and liver function

No dosage adjustment is required in the presence of impaired renal and liver function.

ហាមប្រើចំពោះ៖
- អ្នកធ្លាប់មានប្រតិកម្មជាមួយ Pantoprazole។
- ស្ត្រីមានផ្ទៃពោះ ស្ត្រីបំបៅកូន និងកុមារ (ដោយមិនទាន់បានសាកល្បង)។
- អ្នកខ្សោយថ្លើមធ្ងន់ធ្ងរ។

hypersensitivity to Pantoprazole.

Safety and efficacy in children have not been established. Severely impaired liver function.

ផលរំខាន៖ ឈឺក្បាល ឈឺពោះ រាក ទល់លាមក ហើមពោះ ឡើងកន្ទួលក្រហម រមាស់ស្បែក ឡើងកន្ទាលត្រអាក ស្ហុកអាណាហ្វ៊ីឡាក់ទិច។ ក្នុងករណីកម្រ៖ ចង្អោរ វិលមុខ ស្រវាំងភ្នែក ធ្លាក់ទឹកចិត្ត ឡើងកំដៅ ឈឺសាច់ដុំ...។

Headache and gastro-intestinal complaints such as upper abdominal pain, diarrhoea, constipation or flatulence have been reported. With continued treatment complaints usually diminish. There have been reports of allergic reactions such as skin rash, pruritus and in isolated cases also urticaria, angioedema or anaphylactic shock. There have been less frequent reports of nausea, dizziness or disturbances in vision (blurred-vision). Peripheral edema, depression, fever or myalgia have been reported in individual cases.

ឱសថនេះពុំមានអន្តរកម្មជាមួយចំណីអាហារ, ឱសថប្រឆាំងនឹងអាស៊ីត, Ketoconazole, Cytochrome P450, Antipyrine, Diazepam, Theophilline, Digoxine, Oral contraceptive, Phenytoin, Nifedipine, Carbamazepine, Diclofenac, Metoprolol, Glibenclamide, Ethanol, Caffeine, Warfarine,...។

Concomitant intake of food has no influence on the bioavailability.

Pantoprazole may reduce or increase the absorption of drugs whose bioavailability is PH-dependant e.g. ketoconazole.

Studies in humans reveal no interaction with the cytochrome P450-system of the liver. There was no induction of the cytochrome P450-system after chronic administration as shown with marker antipyrine and no interactions were observed after concomitant administration of Pantoprazole with either antipyrine, diazepam, theophylline, digoxin, oralconraceptiveshenytoin, nifedipine, carbamazepine, diclofenac, metoprolol, glibenclamide, ethanol and caffeine.

Concomitant administration of warfarin or phenprocoumon has no influence on its effect on coagulation factors.

Antacid do no interact with Pantoprazole.

ហាមប្រើចំពោះស្ត្រីមានផ្ទៃពោះ ស្ត្រីបំបៅកូន (ដោយមិនទាន់បានសាកល្បង)។

Safety in pregnancy and during lactation has not been established.

ការប្រុងប្រយ័ត្ន៖
- មិនត្រូវប្រើឱសថនេះក្នុងការព្យាបាលវិបត្តិក្រពះស្រាលៗទេ ដូចជា ពិបាករំលាយអាហារជាដើម។
- មុនប្រើឱសថនេះ ត្រូវធានាថាអ្នកជំងឺពុំមាន ដំបៅមហារីកក្រពះ បំពង់អាហារទេ ព្រោះការប្រើឱសថនេះអាចកាត់បន្ថយរោគសញ្ញាមហារីកនាំអោយពិបាកព្យាបាលទៅថ្ងៃក្រោយ។
- ត្រូវធ្វើរោគវិនិច្ឆ័យ រលាកបំពង់អាហារ ដោយប្រើ Endoscopy។

Pantoprazole is not indicated for mild gastro-intestinal complaints such as nervous dyspepsia. Prior to treatment, the possibility of a malignant gastric ulcer or a malignant disease of the oesophagus should be exclude, as the treatment with Pantoprazole may alleviate the symptoms of malignant ulcer and can thus delay diagnosis.

Diagnosis of reflux oesophagitis should be confirmed by endoscopy.

Pantoprazole is proton pump inhibitor, i.e., it inhibits specifically and dose proportionally H+,K+- ATPase the enzyme which is responsible for gastric acid secretion in the parietal cells of the stomach.

Pantoprazole is a substituted benzimidazole which accumulates in the acidic components of the parietal cells after absorption. In the parietal cell it is protonated and chemically rearranged to the active inhibitor, a cyclic sulphenamide, which binds to the H+,K+-ATPase thus inhibiting the proton pump and causing suppression of stimulate and basal gastric acid secretion after oral Pantoprazole dosing. Because Pantoprazole acts distal to the receptor level, it can influence gastric acid secretion irrespective of the nature of the stimulus.

Pantoprazole exerts its full effect in a strongly acidic environment (pH<3) and remains mostly inactive at higher pH values, which explains its selectivity for the acid secreting parietal cells of the stomach. Therefore, the complete pharmacological and therapeutic effect for Pantoprazole can only be achieved in the acid-secreting parietal cells. By means of feedback mechanism this effect is diminished at the same, rate as acid secretion is inhibited.